- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05290558
The Therapeutic Effects of Bu Shen Yi Jing Pill on Semen Quality in Sub Fertile Males: a Randomized Controlled Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Subfertility is defined as a failure to conceive after 1 year of regular unprotected intercourse. Impaired fertility affects 10 to 15% of couples and male factor is the cause of subfertility in 25 to 40% of couples. With increasing paternal age, semen volume, sperm motility and the percentage of sperm with normal morphology decreases. The majority of men who present with subfertility have either abnormal sperm density, motility or morphology, or a combination of the above, and treatment for this condition is varied and empirical.
There is a paucity of studies and randomized controlled trials to guide treatment of male factor subfertility. Various antioxidant formulations and multivitamins have been used empirically but have not been shown consistently to improve sperm counts and viability. When treatment fails, assisted reproduction will be the last resort. All assisted reproduction treatments are associated with medical, financial and emotional burden. Given the lack of proven treatment options in Western Medicine, Traditional Chinese Medicine (TCM) may provide a viable complementary treatment option. One such option is the Bu Shen Yi Jing (BSYJ) pill.
A clinical observational study conducted by the team in Singapore Thong Chai Medical on subfertile male patients with poor sperm quality and a body constitution of Kidney Deficiency showed that 2 courses of BSYJ pill over a 6 months' duration resulted in successful conception of 33% of azoospermic male patients (n = 60). In a subgroup of patients where serial sperm analysis was available (n=10), the percentage of sperm with grade A motility increased from a median of 22.6 ± 2.4% pre-treatment to 35.1 ± 3.2% post treatment (p < 0.05); and the hyaluronic binding assay improved from 33.2 ± 2.4% to 72 ± 4.6% (p < 0.05). This suggests that BSYJ pills possibly works on improving the motility of the sperms in patients having the Kidney deficiency body constitution.
As such, this study aims to validate these hypotheses and anecdotal evidence by conducting a safety and efficacy study of the BSYJ pill on a prospective cohort.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Tat Xin Ee, MD
- Phone Number: 97717807
- Email: ee.tat.xin@singhealth.com.sg
Study Contact Backup
- Name: Chee Wai Ku, MD
- Phone Number: 98365742
- Email: gmskcw@nus.edu.sg
Study Locations
-
-
-
Singapore, Singapore, 229899
- Recruiting
- KK Women's and Children's Hospital
-
Contact:
- Tat Xin Ee, MD
- Phone Number: 97717807
- Email: ee.tat.xin@singhealth.com.sg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Duration of subfertility (both primary and secondary) ≥ 1 year;
Any or combination of the three abnormal semen parameters, defined according to the 2010 WHO criteria, including
- Oligozoospermia, with sperm concentration less than 15 x 10^6,
- Teratozoospermia, with normal sperm morphology less than 4%, and
- Asthenozoospermia, with total sperm motility less than 40%, or progressive sperm motility less than 32%.
- Diagnosed with TCM syndrome of Kidney Deficiency Based on a prominent TCM diagnosis textbook known as TCM Diagnostics, the main symptoms patients need to fulfil for Kidney Deficiency are either nocturnal polyuria or lower back pain. In addition, patients need to fulfil any 1 of the secondary symptoms, including fatigue; dizziness; tinnitus or deafness; memory loss; excessive urination; low libido; wet dreams; premature ejaculation; presence of feverish palms and soles or night sweats; dry mouth or throat; cold intolerance or preference for warmth; poor sleep quality. Presence of both 1 main symptom and 1 secondary symptom allows for the diagnosis of the Kidney Deficiency syndrome.
Patients who meet all three criteria mentioned above will be included in the study.
Exclusion Criteria:
- Azoospermia and severe oligoasthenoteratozoospermia;
- Aspermia;
- Varicocele;
- Recent urogenital infections;
- Y chromosome deletions;
- Abnormal karyotypes
- History of chemotherapy and / or radiotherapy;
- Patients on fertility supplements or supplements marketed to improve fertility;
- Patients with uncontrolled diabetes or/and hypertension; with uncontrolled chronic medical conditions
- Patients currently already on BSYJ pills treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
Patients in this arm will be given a placebo pill that resembles the actual Bu Shen Yi Jing Pill.
|
Placebo contains the ingredients: grounded black rice and permitted colouring. The ingredients are encapsulated within a gelatine capsule. Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year
Other Names:
|
ACTIVE_COMPARATOR: Bu Shen Yi Jing Pill
Patients in this arm will be given the BSYJ Pill.
|
Bu Shen Yi Jing Pill contained Radix Pseudostellaria, Fructus Lycii, Radix Et Rhizoma Salviae, Rhizoma Dioscorea, Semen Plantaginis, Semen Cuscuta, Patriniae Herba, Herba Epimedii, Radix Ophiopogonis, Fructus Rubi, Fructus Corni, Bupleurum roots, Fructus Schisandrae Chinensis, Radix Et Rhizoma Glycyrrhizae. Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the change in sperm volume from baseline after treatment with BSYJ pill
Time Frame: 1 year
|
From sperm samples analyses
|
1 year
|
To determine the change in sperm morphology from baseline after treatment with BSYJ pill
Time Frame: 1 year
|
From sperm samples analyses
|
1 year
|
To determine the change in sperm motility from the baseline after treatment with BSYJ pill
Time Frame: 1 year
|
From sperm samples analyses
|
1 year
|
To determine the change in sperm concentration from the baseline after treatment with BSYJ pill
Time Frame: 1 year
|
From sperm samples analyses
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the clinical pregnancy rate and successful delivery rate after BSYJ pill
Time Frame: 2 year
|
Defined by the number of pregnancies and subsequent actual births after commencement of BSYJ pill
|
2 year
|
To study the safety and determine the changes in blood profile after treatment with BSYJ pill
Time Frame: 1 year
|
Defined by changes in participant's full blood count, renal panel, liver function test and hormone profile.
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the common side effects of the BSYJ pill
Time Frame: 1 year
|
Participant reported symptoms of excessive heat syndrome such as ulcers and mouth dryness.
|
1 year
|
To assess the common gastrointestinal side effects of the BSYJ pill
Time Frame: 1 year
|
Participant reported symptoms of gastrointestinal symptoms such as indigestion and appetite reduction.
|
1 year
|
To evaluate safety profile of BSYJ pill
Time Frame: Up to 1 year after recruitment
|
Participants will be assessed frequently to pick up any side effects noted after commencement of BSYJ pill
|
Up to 1 year after recruitment
|
Change from baseline severity based on TCM symptom scoring questionnaire
Time Frame: 1 year
|
As BSYJ pills target the TCM syndrome of Kidney Qi deficiency, symptoms related to Kidney Qi deficiency syndrome, which includes frequent urination and back pain, fatigue and dizziness, may be improved through this research.
|
1 year
|
Number of participants with improvement in TCM syndrome of Kidney Qi deficiency from baseline according to the TCM symptom scoring questionnaire Stagnation
Time Frame: 1 year
|
As BSYJ pills target the TCM syndrome of Kidney Qi deficiency, symptoms related to Kidney Qi deficiency syndrome, which includes frequent urination and back pain, fatigue and dizziness, may be improved through this research.
|
1 year
|
Patient's basic demographics
Time Frame: 1 year
|
Defined by age, ethnicity, marital status
|
1 year
|
Patient's partner's basic demographics
Time Frame: 1 year
|
Defined by age, ethnicity, marital status
|
1 year
|
Patients's anthropometry
Time Frame: 1 year
|
Defined by height, weight and body mass index based on weight (kg) /height (m)2
|
1 year
|
Number of participants who smoke
Time Frame: 1 year
|
Self-reported
|
1 year
|
Number of participants who take alcohol regularly
Time Frame: 1 year
|
Self-reported based on the amount and frequency of alcohol intake
|
1 year
|
Number of participants who have dietary restrictions
Time Frame: 1 year
|
Self-reported
|
1 year
|
Number of participants with occupational exposures to chemicals
Time Frame: 1 year
|
Self-reported
|
1 year
|
Number of participants with exposure to hot baths or jacuzzi
Time Frame: 1 year
|
Self-reported
|
1 year
|
Number of participants who uses recreational drugs
Time Frame: 1 year
|
Self-reported
|
1 year
|
Number of participants who exercise regularly
Time Frame: 1 year
|
Self-reported
|
1 year
|
Number of patients with significant medical history
Time Frame: 1 year
|
Self-reported details of medical history
|
1 year
|
Number of patients with significant surgical history
Time Frame: 1 year
|
Self-reported details of surgical history
|
1 year
|
Number of patients on regular medications
Time Frame: 1 year
|
Self-reported details of types of regular medications
|
1 year
|
Number of patients with drug allergies
Time Frame: 1 year
|
Self-reported details of drug allergies
|
1 year
|
Number of patients who take supplements
Time Frame: 1 year
|
Self-reported details of the type of supplements taken
|
1 year
|
Number of patients who take steroids
Time Frame: 1 year
|
Self-reported
|
1 year
|
Number of patients with previous history of sexually transmitted disease
Time Frame: 1 year
|
Self-reported details of sexually transmitted disease
|
1 year
|
Number of patients with previous history of genital trauma
Time Frame: Since birth
|
Self-reported details of genital trauma
|
Since birth
|
Patient's fertility history
Time Frame: 1 year
|
Determined by the number of years of attempts at conception, sexual intercourse frequency, number of paternity (including current and/or previous partners), previous fertility treatments and medications
|
1 year
|
Patient's partner's fertility history
Time Frame: 1 year
|
Determined by the number of years of attempts at conception, sexual intercourse frequency, number of maternity (including current and/or previous partners), previous fertility treatments and medications, and menstrual history
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Tat Xin Ee, MD, KK Women's and Children's Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020/2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
Istanbul University - Cerrahpasa (IUC)RecruitingInfertility | Sexual Dysfunction | Infertility, Male | Nurse's Role | Sexuality | Infertility; FemaleTurkey
Clinical Trials on Placebo Drug
-
Novus Therapeutics, IncCompletedHealthy Adult VolunteersUnited States
-
Regor Pharmaceuticals Inc.Recruiting
-
Helixmith Co., Ltd.CompletedOsteoarthritis of the Knee
-
Novus Therapeutics, IncCompleted
-
Shanghai HEP Pharmaceutical Co., Ltd.CompletedHepatitis B, ChronicChina
-
Shanghai HEP Pharmaceutical Co., Ltd.Completed
-
ActivX Biosciences, Inc.Kyorin Pharmaceutical Co.,LtdCompleted
-
Daiichi Sankyo, Inc.Syneos HealthCompletedFibromyalgiaSpain, United States, Poland, Bulgaria, South Africa, Hungary, Czechia, Romania
-
Novartis PharmaceuticalsRecruitingResistant HypertensionChina, Italy, Spain, France, Netherlands, Taiwan, Germany, Czechia, Australia, Japan, United States, Bulgaria, United Kingdom, Poland, Austria, Slovakia
-
Medesis Pharma SATerminated